Capecitabine
34 NDCs across 16 manufacturers|34 Generic,0 Brand
Capecitabine is used to treat breast neoplasms and colorectal neoplasms, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Apr 30, 1998, and the first generic was approved Sep 16, 2013. FDA's Orange Book lists 20 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $35K on Capecitabine across 162 claims for 50 beneficiaries.
Capecitabine is available as 34 NDCs from 16 manufacturers (34 generic, 0 brand), with NADAC prices from $0.36 to $0.53 per EA — a 45% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
34
34G / 0B
Manufacturers
16
competing in market
Price Spread
$0.36 – $0.53
per EA
7d Activity
avg -2.6% WoW · of 34 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
BluePoint Laboratories manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Nucleoside Metabolic Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
16 manufacturers producing CAPECITABINE
Frequently Asked Questions
What is Capecitabine used to treat?
Capecitabine is used to treat breast neoplasms and colorectal neoplasms, per the National Library of Medicine's MED-RT classification.
When did Capecitabine become available as a generic?
FDA approved the first generic Capecitabine (ANDA) on Sep 16, 2013. The Orange Book currently lists 20 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Capecitabine?
In 2024, Medicare Part D spent $35K on Capecitabine across 162 claims for 50 beneficiaries.
How many Capecitabine products are on the market?
The Capecitabine drug market contains 34 NDCs from 16 manufacturers — 34 generic and 0 brand products.
What is the price range for Capecitabine?
NADAC reference prices for Capecitabine range from $0.3615 to $0.5258 per EA — a 45% difference between cheapest and most expensive.
Which manufacturers make Capecitabine?
16 manufacturers list Capecitabine in NADAC. Ranked by number of NDCs, the largest are BluePoint Laboratories (4), NorthStar Rx LLC (3), Camber Pharmaceuticals Inc. (3), Sun Pharmaceutical Industries Inc. (2), Armas Pharmaceuticals Inc. (2).
How has the price of Capecitabine changed recently?
Over the past 7 days, 0 Capecitabine NDCs rose and 15 fell, with a market-wide average change of -2.6%.